Dare Bioscience (DARE) Stock Price

Dare Bioscience Price

NASDAQ·CLOSED
0.72
​
Market closed

Over the last 14 years Dare Bioscience grew revenue by 9.1% annually, reaching 1.03 M USD. For Dare Bioscience, the net margin of -1,300.7% is down versus -387.0% a few years ago.

Dare Bioscience stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dare Bioscience business model & stock analysis

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2014-04-10. The firm is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The firm is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.

Frequently asked questions about Dare Bioscience

9 analysts currently rate the Dare Bioscience stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Dare Bioscience to generate revenue of 2.72 M USD and earnings per share of -0.76 USD.

Converted at the current exchange rate, the Dare Bioscience share trades at 0.64 EUR (0.72 USD).

The Dare Bioscience share (DARE) is listed on 1 stock exchanges, including: NASDAQ (DARE).

The expected revenue of Dare Bioscience is 2.72 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Dare Bioscience is -11.05 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Dare Bioscience is currently -0.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dare Bioscience stock.

The price-to-sales ratio (P/S) of Dare Bioscience is currently 3.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dare Bioscience stock.

The Eulerpool Quality Score for Dare Bioscience is 3/10.

The ISIN of Dare Bioscience is US23666P2002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Dare Bioscience is A2DU45. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Dare Bioscience is DARE. The ticker symbol is used to trade Dare Bioscience shares on the stock exchange.

Fair ValueTerminal
0.61 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
49,056.81 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Apr 10, 2014
ISIN
US23666P2002
Cusip
23666P101
Sedol
BYPCSL5
Market capitalization
10.32 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-0.95
P/Ee 2027
-1.77
P/Ee 2028
6.02
P/Ee 2029
0.48
P/Ee 2030
0.15
P/Se
3.85
EV/EBIT
0.87
P/B Ratio
3.63
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-243.68 %
Last updated Oct 22, 2026, 2:24 AM